Belatacept (DrugBank: Belatacept)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00279760 (ClinicalTrials.gov) | January 2000 | 18/1/2006 | Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis | A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Belatacept;Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | 65 Years | Both | 210 | Phase 1;Phase 2 | United States;Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom |